CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for chlorthalidone; clonidine hydrochloride and what is the scope of freedom to operate?

Chlorthalidone; clonidine hydrochloride is the generic ingredient in three branded drugs marketed by Par Pharm, Natco Pharma, and Boehringer Ingelheim, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	5
Clinical Trials:	2
DailyMed Link:	CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Conselho Nacional de Desenvolvimento Científico e Tecnológico	Phase 4
Instituto do Coracao	Phase 4
VA Office of Research and Development

See all CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

C02AC	Imidazoline receptor agonists
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

N02CX	Other antimigraine preparations
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Par Pharm	CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	071179-001	Dec 16, 1987		DISCN	No	No
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-003	Apr 10, 1984		DISCN	Yes	No
Natco Pharma	CLORPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	071325-003	Feb 9, 1987		DISCN	No	No

Expired US Patents for CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-001	Approved Prior to Jan 1, 1982	3,454,701
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-002	Approved Prior to Jan 1, 1982	3,454,701
Boehringer Ingelheim	COMBIPRES	chlorthalidone; clonidine hydrochloride	TABLET;ORAL	017503-003	Apr 10, 1984	3,454,701

Market Dynamics and Financial Trajectory for CHLORTHALIDONE and CLONIDINE HYDROCHLORIDE

Last updated: February 13, 2026

---

What is the current market landscape for CHLORTHALIDONE and CLONIDINE HYDROCHLORIDE?

Chlorthalidone and clonidine hydrochloride are established antihypertensive agents with decades of use. Their markets are characterized by mature, stable demand, driven primarily by the large population affected by hypertension.

Market Size and Revenue Estimates

• Chlorthalidone:

  • Estimated global market value in 2022: approximately $400 million.
  • Market primarily composed of generic formulations.
  • Major markets include the US, Europe, and Asia-Pacific, with the US accounting for over 60% of sales.
  • Market growth is modest, with a CAGR of roughly 2-3% forecast through 2027, driven by continued prescribing and patent expirations.

• Clonidine Hydrochloride:

  • Estimated global market value in 2022: around $150 million.
  • Used in various formulations, including patches and tablets.
  • Growth rate projected at 1-2% annually; growth hindered by the availability of newer antihypertensive drugs.

Patent and Regulatory Factors

• Chlorthalidone:

  • Patent expired in the early 2000s.
  • Market predominantly in generics; limited innovation due to its age.
  • No new formulations or formulations with extended-release status, which constrains market expansion.

• Clonidine Hydrochloride:

  • Patent expired in the late 20th century.
  • Currently off-patent, with a high percentage of generic products.
  • However, newer formulations like clonidine patches have received regulatory approval, maintaining some market share.

Key Drivers and Challenges

• Drivers:

  • Aging populations and increasing prevalence of hypertension.
  • Generic drug adoption reducing prices and expanding access.
  • Growing use in combination therapies for resistant hypertension.

• Challenges:

  • Competition from newer agents (ACE inhibitors, ARBs, calcium channel blockers).
  • Side effect profiles—sedation and dry mouth for clonidine; electrolyte disturbances for chlorthalidone—may limit use.
  • Price sensitivity in developing markets limits profitability.

---

Financial Trajectory and Future Outlook

Aspect	Chlorthalidone	Clonidine Hydrochloride
Revenue Trends (2022)	~$400 million	~$150 million
Growth Outlook	Slight CAGR of 2-3% through 2027	1-2% CAGR through 2027
Patent Status	Expired	Expired
Innovation & Formulation Pipeline	Minimal, mainly generics	Limited, mainly reformulations (patches)
Regulatory Environment	Stable, no new approvals for novel formulations	Stable, with some approvals for patches

Market Entry and Expansion Opportunities

• Development of extended-release formulations to improve compliance.
• Combination formulations with other antihypertensives.
• Entry into emerging markets with high hypertension prevalence.

Regulatory and Policy Impact

• Broad adoption of generics reduces revenue potential for branded versions.
• Health authorities focus on lowering drug costs, favoring generic distribution.
• Potential incentive for biosimilars or new formulations, though risk is limited due to market maturity.

---

Key Market Trends

• Shift toward individualized therapy increases demand for formulations with better adherence.
• Growth in OTC or lower-cost alternatives in developing countries.
• Increased use of combination pills reduces overall pill burden and improves compliance.

---

Summary

Chlorthalidone and clonidine hydrochloride are mature drugs with stable, although slowing, markets. Their revenues rely heavily on generics, with incremental growth expected through formulation improvements and market penetration in emerging economies. Competition from newer antihypertensives presents ongoing pressure. No significant patent protections exist, limiting future premium pricing or innovation-driven revenue expansion.

---

Key Takeaways

• The markets for chlorthalidone and clonidine hydrochloride are mature with stable growth.
• Revenue is primarily from generic sales across developed and developing regions.
• Innovation efforts focus on newer formulations rather than new chemical entities.
• Market expansion depends on formulation improvements and new combinations.
• Competition from newer classes limits long-term growth prospects.

---

FAQs

Q1: How does the patent expiration affect market potential?
A: Patent expiration shifts sales to generics, reducing prices and profit margins, but expands market access. The opportunity for innovation diminishes, limiting premium pricing.

Q2: Are there opportunities for branded versions?
A: Limited, given the maturity of the drugs and prevalence of generics; growth prospects rely on reformulations or combination therapies.

Q3: Which regions are driving growth?
A: The US leads in revenue, but emerging markets in Asia-Pacific and Latin America present growth opportunities due to rising hypertension rates.

Q4: How does competition impact pricing?
A: Increased generic competition drives down prices, exerting pressure on margins, especially in price-sensitive markets.

Q5: What is the outlook for future research and development?
A: Focused on reformulations—such as patches or extended-release tablets—rather than new chemical entities, given low pipeline activity.

---

Sources:

1. IQVIA, 2022 Market Insights.
2. GlobalData, Antihypertensive Drugs Report 2022.
3. FDA and EMA approval databases.
4. Published market analysis and patent expirations.
5. Company annual reports and press releases.